Insmed receives EC approval for Brinsupri to treat NCFB
Insmed has received approval from the European Commission (EC) for Brinsupri (brensocatib 25 mg tablets) to treat non-cystic fibrosis bronchiectasis…
Respiratory
-
-
Alkermes to acquire Avadel for $2.1bn
Alkermes has agreed to acquire Avadel Pharmaceuticals for up to $20 per share in cash, valuing Avadel at $2.1bn. The…
-
GSK plans $30bn investment for R&D in US
GSK has announced an investment of $30bn in the US over the next five years for research and development (R&D)…
-
China’s NMPA conditionally approves Boehringer’s tablets for NSCLC
China's National Medical Products Administration (NMPA) has granted conditional approval to Boehringer Ingelheim's Hernexeos (zongertinib tablets), for use as a…
-
FDA awards breakthrough therapy status to BMS and SystImmune’s NSCLC drug
Bristol Myers Squibb and SystImmune have announced breakthrough therapy designation from the US Food and Drug Administration (FDA) for izalontamab…
-
Insmed wins FDA approval for future blockbuster Brinsupri
Insmed's drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed dipeptidyl peptidase 1 (DPP1)…
-
Fosun and Expedition make $645m licensing deal for respiratory drug
Fosun Pharma's subsidiary, Fosun Pharma Industrial, has entered a licence agreement to grant ex-China rights for its experimental respiratory drug,…
-
Hengrui Pharma and GSK link across key therapeutic areas
Hengrui Pharma has signed an agreement with GSK for the development of up to 12 innovative medicines across several therapeutic…
-
Apnimed sets sights on sleep apnoea pill approval following Phase III win
Following the success of its second Phase III trial on its investigative sleep apnoea medication, Apnimed has doubled down on…
-
Vertex and NHS England agree reimbursement for Alyftrek
Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, Alyftrek (deutivacaftor/tezacaftor/vanzacaftor). This follows…
